Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells.

Molecular & cellular proteomics : MCP - 1 Jul 2017

Roolf Catrin, Dybowski Nikolaj, Sekora Anett, Mueller Stefan, Knuebel Gudrun, Tebbe Andreas, Murua Escobar Hugo, Godl Klaus, Junghanss Christian, Schaab Christoph

Abstract excerpt

Constitutively activating internal tandem duplication (ITD) alterations of the receptor tyrosine kinase FLT3 (Fms-like tyrosine kinase 3) are common in acute myeloid leukemia (AML) and classifies FLT3 as an attractive therapeutic target. So far, applications of FLT3 small molecule inhibitors have been investigated primarily in FLT3-ITD+ patients. Only recently, a prolonged event-free survival has been observed in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to fms-Like Tyrosine Kinase 3
Share to Gene Regulatory Networks

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inhibitory Concentration 50

Share to Niacinamide

Share to Phenylurea Compounds

Share to Phosphoproteins

Share to Proteomics

Share to Sorafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 28450419
DOI: 10.1074/mcp.M117.067462
PMCID: PMC5500767

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells.PMID 28450419Read ↗

Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation.Semantic proximity Read ↗

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.Semantic proximity Read ↗

Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.Semantic proximity Read ↗

Inhibition of FLT3 in AML: a focus on sorafenib.Semantic proximity Read ↗

A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients.Semantic proximity Read ↗

Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemiaSemantic proximity Read ↗

A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patientsSemantic proximity Read ↗

Genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways mediating sorafenib resistance in acute myeloid leukemia.Semantic proximity Read ↗

FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.Semantic proximity Read ↗

The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.Semantic proximity Read ↗

Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.Semantic proximity Read ↗

Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.